Courtney Perkins
Adult Health · Glen Burnie, MDNPI 1184196024
Payments from drug & device makers
Across 159 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$752
- Novo Nordisk$312
- Pfizer$248
- Astellas Pharma US Inc$206
- GSK$176
- AstraZeneca$156
- plus $887 from 17 others
What the payments were for
- Food & beverage$2,67298%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $752 |
| Novo Nordisk | 26 | $312 |
| Pfizer | 14 | $248 |
| Astellas Pharma US Inc | 8 | $206 |
| GSK | 9 | $176 |
| AstraZeneca | 9 | $156 |
| Lilly USA, LLC | 9 | $151 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $95 |
| Kowa Pharmaceuticals America, Inc. | 4 | $86 |
| Amarin Pharma, Inc. | 4 | $78 |
| Axsome Therapeutics, Inc. | 3 | $74 |
| Bayer | 3 | $67 |
| Boehringer Ingelheim | 3 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Amgen(2 entities) | 2 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Merck | 2 | $34 |
| Dexcom, Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $16 |
| Abbott | 1 | $16 |
| Novartis | 1 | $14 |
How this compares
$2,737 in reported general payments places this provider in the 80th percentile of 542 adult health providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $61,805 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $44,755 |
| OzempicSemaglutide | 25 | $33,733 |
| MounjaroTirzepatide | 16 | $25,603 |
| RybelsusSemaglutide | 13 | $21,114 |
| XareltoRivaroxaban | 12 | $9,726 |
| Metoprolol Succinate | 108 | $2,722 |
| Pravastatin Sodium | 69 | $2,675 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,347 |
| SynthroidLevothyroxine Sodium | 27 | $2,298 |
| Atorvastatin Calcium | 185 | $2,133 |
| Losartan Potassium | 110 | $1,737 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,653 |
| Rosuvastatin Calcium | 81 | $1,602 |
| Ezetimibe | 28 | $1,562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $248 | $61,80540 claims |
| Novo NordiskOzempic, Rybelsus | $312 | $54,84738 claims |
| GSKTrelegy Ellipta | $176 | $44,75537 claims |
| Lilly USA, LLCMounjaro | $151 | $25,60316 claims |
| AbbVieSynthroid | $752 | $2,29827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 542 adult health providers in Maryland.
Other adult health in Glen Burnie
- Lucia NovakCamp Springs$473K
- Caroline RuhlAnnapolis$315K
- Joyce MiskovicHighland$264K
- Christopher RobersonBaltimore$180K
- Amit DhirBaltimore$97K
- Angie PriceBaltimore$96K
- Morgan JoliatSykesville$92K
- Brendon BowerBaltimore$64K
- Caitlin NassBaltimore$46K
- Jane KapustinClarksville$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.